Nxera Pharma Secures US$22.5 Million As Partner Neurocrine Launches Phase 2 Trial For Schizophrenia Drug NBI-1117570
Nxera Pharma Co., Ltd. secures US$22.5M milestone as Neurocrine begins Phase 2 trial of NBI-1117570 to treat schizophrenia, evaluating safety and efficacy in adults.
Breaking News
Apr 13, 2026
Simantini Singh Deo
Nxera Pharma Co., Ltd. announced that its development partner, Neurocrine Biosciences Inc., has begun a Phase 2 clinical study for the investigational drug NBI-1117570, also known as NBI-’570. The first patients in the study have already been enrolled and dosed. With this progress, Nxera is set to receive milestone payments totaling US$22.5 million from Neurocrine, which will be recorded as revenue in the first quarter of FY2026.
NBI-’570 is an experimental oral medication designed as a dual muscarinic M1/M4 receptor agonist. The compound was discovered using Nxera’s proprietary NxWave drug discovery platform, which focuses on creating next-generation small-molecule therapies.
Christopher Cargill, President and CEO of Nxera Pharma, stated that the start of this Phase 2 trial represents another important achievement in the long-standing and productive partnership between the two companies. He explained that NBI-’570 is the second compound created through the NxWave platform to advance into Phase 2 testing within Neurocrine’s muscarinic agonist program.
He noted that schizophrenia continues to have significant unmet medical needs, and the company believes this new compound may offer meaningful improvements for patients. He also shared that Nxera looks forward to providing more updates as the broader muscarinic agonist portfolio progresses.
The Phase 2 clinical trial (NCT07288333) is structured as a double-blind, placebo-controlled study. Its purpose is to evaluate the effectiveness, safety, and tolerability of NBI-’570 in adults with schizophrenia who require in-patient treatment. The study plans to enroll about 120 participants.
The primary endpoint focuses on changes from baseline in the Positive and Negative Syndrome Scale (PANSS) total score, which is widely used to assess symptom severity in schizophrenia. A key secondary endpoint will involve monitoring treatment-emergent adverse events (TEAEs) to understand the drug’s safety profile.
Also Read :
